Trial reportScientific reports2025
Efficacy and safety of analgesic-eluting urethral catheter after urogynecological surgery: a prospective randomized controlled trial.
Trial report in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Catheter-related bladder discomfort (CRBD) and urethral pain are frequent issues following urethral catheterization, particularly after urogynecological procedures. This study evaluates the efficacy and safety of a ropivacaine-eluting urethral catheter in reducing CRBD. Sixty female patients undergoing urogynecological surgery were randomized into three groups: Control arm, 0.5% ropivacaine 1 mL/hr (Study arm 1), and 0.5% ropivacaine 2 mL/hr (Study arm 2), with 20 patients each. CRBD incidence and severity at 24 h postoperatively were assessed. Adverse events and patient discomfort were evaluated as secondary outcomes. Baseline demographics including age, ASA score, body mass index, and surgery type were not significantly different among groups (all p > 0.05). CRBD incidence was 65.0% (Control arm), 36.8% (Study arm 1), and 21.1% (Study arm 2) (p = 0.018). CRBD severity was significantly lower in both study arms compared to control (p < 0.001). No significant differences in adverse events were observed among groups. Catheter-related discomfort(p = 0.008) and patient preference for future reuse of catheter (p = 0.004) differed significantly. An appropriate dose of ropivacaine eluting urethral catheter significantly reduced the incidence and severity of CRBD and the discomfort with catheter usage in patients undergoing urogynecological surgery without significant adverse events while achieving preference for future reuse of analgesic-eluting catheters.Registry: The Clinical Research Information Service (CRIS), Number: KCT0010934, Registration date: 22nd August 2025. (Direct link: https://cris.nih.go.kr/cris/search/detailSearch.do?search_lang=E&focus=reset_12&search_page=L&pageSize=10&page=undefined&seq=31096&status=5&seq_group=31066).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.